William Blair served as financial advisor and capital markets advisor to Haymaker Acquisition Corp. III (NASDAQ: HYAC), a publicly traded special purpose acquisition company (SPAC) in connection with its merger with Biote. The transaction was announced on December 13, 2021 and closed on May 27, 2022.
About the Companies
Biote is a category-creating, consumer-directed health and wellness company. The company is transforming healthcare outcomes for the large and growing population segment experiencing hormone imbalance, a widespread problem, impacting approximately 200 million Americans, that increases with age, enhances the risk of chronic disease and is vastly undertreated. Biote is addressing this problem through hormone optimization and driving long-term patient satisfaction. The company delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support. The company derives revenues by contractually sharing in the profit generated by Biote-certified practitioners and through the sale of its Biote-branded nutraceutical products. Biote-certified practitioners deliver personalized hormone replacement therapy. Since its founding in 2012, Biote has grown its network of medical providers to 4,700 practitioners in the U.S. Biote-certified practitioners administer bioidentical hormone therapy via a simple in-office procedure, providing a convenient solution to a broad, underserved patient population.
Haymaker Acquisition Corp. III is a blank check company formed for the purpose of effecting a business combination, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Haymaker is led by Chief Executive Officer and Executive Chairman, Steven J. Heyer; President, Andrew R. Heyer; and Chief Financial Officer, Christopher Bradley.
Learn more about our consumer and retail investment banking expertise.